Urology Doctors in Snellville, GA Accepting Medicare

9 Urology doctors found. Showing 1 - 9

Dr. Neal Patel, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1557 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900    Fax: 678-344-8900

Naveen Kumar Arora, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1557 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900    Fax: 404-492-7021

Dr. John Stites Iv, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1700 Tree Ln Ste 420, Snellville, GA 30078 Phone: 770-979-9427

A Paul Sherlag, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1700 Tree Ln, Suite 420, Snellville, GA 30078 Phone: 770-979-9427    Fax: 770-972-3846

Dr. Jitesh Vinod Patel, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1555 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900    Fax: 678-666-5201

Dr. Michael D Funderburk, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1557 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900    Fax: 678-666-5201

Ronald E Anglade, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1700 Tree Ln Ste 420, Snellville, GA 30078 Phone: 770-979-9427    Fax: 770-972-3846

Dr. Abhijith Dev Mally, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1557 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900    Fax: 678-666-5201

Dr. Nicholas Farber, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1557 Janmar Rd, Snellville, GA 30078 Phone: 678-344-8900

News Archive

HemaCare second-quarter 2010 revenue increases 4%

HemaCare Corporation announced today profitable second quarter 2010 results with a 4% increase in revenue over the first quarter of the year, and $224,000 of net income, a significant improvement over the first quarter loss of $204,000. The first quarter loss included $184,000 in severance payments to the Company's former Chief Executive Officer and Chief Financial Officer.

Modulation of estrobolome may help lower breast cancer risk

Investigating disparities in the composition of the estrobolome, the gut bacterial genes capable of metabolizing estrogens in both healthy individuals and in women diagnosed with estrogen-driven breast cancer may lead to the development of microbiome-based biomarkers that could help mitigate the risk of certain cancers, according to a review paper published April 22 in the JNCI: Journal of the National Cancer Institute.

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

Study to determine link between insulin glargine and cancer

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association.

Read more Medical News

› Verified 6 days ago